ADMA BIOLOGICS, INC. Depreciation
ADMA BIOLOGICS, INC. (ADMA) reported Depreciation of $900.00 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2020-11-05
- ADMA BIOLOGICS, INC. depreciation for the quarter ending 2020-09-30 was $900.00K, a 50.00% increase year-over-year.
- ADMA BIOLOGICS, INC. depreciation for the quarter ending 2020-06-30 was $700.00K, a 16.67% increase year-over-year.
- ADMA BIOLOGICS, INC. depreciation for the quarter ending 2020-03-31 was $600.00K, a 0.00% change year-over-year.
- ADMA BIOLOGICS, INC. depreciation for the quarter ending 2019-09-30 was $600.00K, a 0.00% change year-over-year.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month |
|---|---|---|---|
| 2020-09-30 | $900.00K 10-Q · filed 2020-11-05 | $1.60M derived: sum of 2 quarters · filed 2020-11-05 | $2.20M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $700.00K 10-Q · filed 2020-08-05 | $1.30M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $600.00K 10-Q · filed 2020-05-06 | ||
| 2019-09-30 | $600.00K 10-Q · filed 2020-11-05 | $1.20M derived: sum of 2 quarters · filed 2020-11-05 | $1.80M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $600.00K 10-Q · filed 2020-08-05 | $1.20M 10-Q · filed 2020-08-05 | |
| 2019-03-31 | $600.00K 10-Q · filed 2020-05-06 | ||
| 2018-09-30 | $600.00K 10-Q · filed 2019-11-06 | $1.20M derived: sum of 2 quarters · filed 2019-11-06 | $1.90M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $600.00K 10-Q · filed 2019-08-08 | $1.30M 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $600.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |